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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: Lenticulostriate vasculopathy is associated with various disorders, in particular
cytomegalovirus infection, which can cause neurological consequences. We wanted to eval-
uate the association of lenticulostriate vasculopathy and cytomegalovirus infection. We retro-
spectively collected data on lenticulostriate vasculopathy from 858 neonatal ultrasonography
scans.
Methods: Fifty-five patients with lenticulostriate vasculopathy were diagnosed. Lenticulostri-
ate vasculopathy was classified as severe and mild according to the ultrasonographic findings.
We analyzed gender, unilateral and bilateral lenticulostriate vasculopathy, mild and severe
lenticulostriate vasculopathy, intrauterine growth retardation, and lenticulostriate vasculopa-
thy associated with other brain malformations to determine whether they were correlated
with cytomegalovirus infection.
Results: Neonatal cytomegalovirus infections correlated primarily with lenticulostriate vascu-
lopathy that was associated with brain structure anomalies p < 0.0001, followed by severe len-
ticulostriate vasculopathy (p Z 0.029). Cytomegalovirus urine polymerase chain reaction
ratios were 69% for severe and 23% for mild lenticulostriate vasculopathy (p Z 0.002; odds
ratio Z 7.33). Of 72 newborns with intrauterine growth retardation without lenticulostriate
vasculopathy, 33 were analyzed for cytomegalovirus, of whom only one was positive, which
was significantly different from the newborns with lenticulostriate vasculopathy (p Z 0.003;Medicine, School of Medicine, Chung Shan Medical University, Number 110, Section 1, Jianguo North
2, Taiwan, ROC.
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Cytomegalovirus Infection in Newborns 409odds ratio Z 11.64).
Conclusion: Lenticulostriate vasculopathy on neonatal ultrasonography is useful for predicting
cytomegalovirus infection, particularly in severe lenticulostriate vasculopathy. When severe
lenticulostriate vasculopathy is associated with a brain structure anomaly, cytomegalovirus
infection should be considered. The outcomes for the cases in which cytomegalovirus infection
was associated with other brain structure anomalies were significantly worse than the out-
comes in cases associated with lenticulostriate vasculopathy only.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Congenital cytomegalovirus (CMV) infection is not uncom-
mon and has been reported to occur in 0.5e2% of all live
births.1e4 It can cause severe neurological consequences
such as hearing loss, neurodevelopmental disability, and
epilepsy. About 40,000 newborns a year (accounting for 1%
of all births in the USA) have been reported to have
congenital CMV,1 and about 5e10% of children with an
asymptomatic CMV infection and 40e50% of those with a
symptomatic CMV infection will develop hearing loss.5
Symptomatic disease is characterized by signs including
microcephaly, hearing loss, migrational brain disorder,
jaundice, petechiae, hepatosplenomegaly, purpura, sei-
zures, lethargy, hypotonia, and poor suck.1,6,7
Additional examinations such as polymerase chain re-
action (PCR) of CMV in urine DNA are suggested for patients
with clinical presentations, and brain magnetic resonance
imaging (MRI) findings such as ventriculomegaly, poly-
microgyria, calcification, cerebellar hypoplasia, and peri-
ventricular white matter damage. However, as these
unspecific findings are not sufficient enough to diagnose
asymptomatic CMV without performing tests for CMV
infection, prompt medication therapy may be delayed
resulting in hearing loss.8e11 Antiviral treatment for new-
borns with congenital CMV infection without evidence of
newborn disease is controversial, especially for the pre-
vention of hearing impairment.10
The definition of lenticulostriate vasculopathy (LSV) is
based on lesions visible on an ultrasound of the brain,
appearing as echogenic streaks or spots in the arteries of
the thalamus and basal ganglia.12 LSV has been reported to
be associated with various congenital disorders including
chromosomal anomalies and congenital infections such as
CMV, and it has been reported to occur in 0.4e5.8% of ne-
onates who have undergone brain ultrasonography.6,13,14 In
one study,12 transfontanelar color Doppler was shown to
display lenticulostriatal blood flow and was used to assess
Stage I LSV (with flow within echogenic changes) and Stage
II LSV (in which the flow disappears, despite the presence of
streaks and spots, which at this stage most probably cor-
responds to calcification). However, the reported etiologies
and outcomes of newborns with LSV are inconsistent,6,12e17
which is probably associated with late sensorineural hear-
ing damage and postnatal CMV infections not found in initial
brain ultrasonography.6,16Most neonates with CMV infection who are asymptomatic
are undetected, especially those with a congenital but
previously unknown CMV infection, and this can eventually
result in the development of impairments.2 Therefore, it is
important to carefully review and correctly interpret brain
ultrasonographic findings for CMV infection in at-risk
neonates.
In comparison to the reported universal CMV screening
tests, brain ultrasonography is a simple and relatively
inexpensive tool that can be used to evaluate LSV, which
may be associated with CMV infection. As the relationship
between LSV and CMV infection is not currently fully un-
derstood, the aim of this study was to evaluate this asso-
ciation in neonates.2. Materials and methods
We retrospectively collected data on LSV from brain ul-
trasonography scans of 858 newborns between June 2010
and May 2012. LSV was defined as multiple or single linear
echogenicity in a bilateral or unilateral basal ganglion or
thalamus. Brain ultrasonography scans were routinely per-
formed in all infants admitted to the neonatal intensive
care unit (NICU, level III) and specialty care nursery (level
II), and outpatients. We measured the diameter of the LSV
lines using an ultrasound system (Acuson X300; Siemens
Medical Solutions USA, Malvern, PA, USA).
LSV cases were categorized into two groups: severe LSV,
at least one line 2.5 mm in brain ultrasonography
(Figure 1B); and mild LSV, echogenic lines < 2.5 mm
(Figure 1A). Congenital CMV infection was defined as a virus
detected by urine PCR up to 3 weeks after birth, and
postnatal infection was defined as a virus detected by urine
PCR from >3 weeks to 12 months after birth.
Gender, unilateral and bilateral LSV in the brain, mild
and severe LSV (Figure 1), intrauterine growth retardation
(IUGR), and LSV associated with brain structural malfor-
mations (Figure 2) were analyzed to investigate their as-
sociation with CMV infection. We also enrolled 72 newborns
with isolated IUGR (50% were symmetric and 50% were
asymmetric) but without LSV as the control group. Intelli-
gence quotients were measured according to age and
classified into cognition and performance quotients. The
scales of cognition and performance quotients were cate-
gorized as: normal (>85), mildly retarded (70e85),
Figure 1 Lenticulostriate vasculopathy (LSV) in two newborns. (A) Mild without a cytomegalovirus (CMV) infection (arrows); and
(B) Patient 13: severe (arrow).
410 S.-Y. Hong et almoderately retarded (from 50 to < 70), and severely
retarded (<50). We classified the neurodevelopmental
outcomes of the patients with CMV into four groups: no
neurological signs and no developmental delay milestones;
mild developmental delay; moderate developmental delay;
and severe developmental delay. At the last follow-up, the
patients were aged between 18 months and 36 months. The
study protocol was approved by the Institute’s Committee
on Human Research of Chung Shan Medical University Hos-
pital (IRB NO.:CS2-15026).
Categorical variables associated with the IUGR and LSV
groups were divided into antenatal, perinatal, and post-
natal. The IUGR patients without LSV had only antenatalFigure 2 Brain ultrasonography depicted severe LSV (right: arro
Patient 12 with a CMV infection.risk factors. The antenatal risk factors associated with IUGR
included placental insufficiency, congenital anomalies, in-
fections, or drug and substance misuse. The antenatal,
perinatal, and postnatal risk factors associated with LSV
included intrauterine infection (mainly CMV), chromosomal
aberrations, infants of diabetic mothers, intrauterine
growth retardation, hypoxic/ischemic conditions during the
delivery process, and central nervous system infections.
Categorical variables between groups were analyzed by
using an independent t test. Linear regression analysis was
used to determine significance and the correlation co-
efficients. All statistical analyses were performed using
SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).w) associated with brain ventriculomegaly (left: arrowhead) in
Table 1 Regression analysis of different factors in 55
newborn infants with lenticulostriate vasculopathy corre-
lated with cytomegalovirus infection.
Factors Correlation
coefficient
Standard
error
p*
Gender (M/F) 0.068 0.101 NS
Bilateral or unilateral LSV 0.044 0.121 NS
Mild or severe LSV 0.260 0.122 0.029
Associated with other
brain anomalies
0.610 0.113 0.000
IUGR 0.065 0.104 NS
Preterm 0.124 0.111 NS
* Significance: p < 0.05.
IUGRZ intrauterine growth retardation; LSVZ lenticulostriate
vasculopathy; NS Z nonsignificant.
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Fifty-five (6.4%) patients were diagnosed with LSV, of whom
44 (80%) were in the NICU, seven (13%) were in the specialty
care nursery, and four (7%) were outpatients (Table S1).
The etiologies associated with LSV were CMV (n Z 20),
chromosome anomalies (n Z 5), those other than brain
congenital anomalies (n Z 8), those other than CMV in-
fections (n Z 7), encephalopathy (n Z 5), and unknown
(n Z 10).
Of the 55 newborns with LSV, 16 were severe and 39
were mild cases (Table S2). The CMV urine PCR ratios were
69% in those with severe LSV and 23% in those with mild LSV
[pZ 0.002; odds ratio (OR)Z 7.33; 95% confidence interval
(CI) Z 1.40e38.43]. Neonatal CMV infections were most
significantly correlated with brain ultrasonography showing
LSV and were associated with brain structure anomalies
(p < 0.001), followed by severe LSV (pZ 0.027; correlation
coefficient: 0.260; Tables 1 and 2). The other factors were
not significant. Of the 11 newborns with severe LSV and
associated brain-structure anomalies, 10 had CMV in-
fections and one had trisomy 13. In the IUGR group (72
newborns with IUGR without LSV) (Table S1), 33 wereTable 2 The positive likelihood ratio of urine cytomegalovirus
Clinical presentation CMV
IUGR without LSV (72) 1
Mild LSV (39) 9
(1) Mild LSV þ IUGR (12) 3
(2) Mild LSV þ brain anomalies (9) 6
(3) Mild LSV þ IUGR þ brain anomalies (4) 3
Severe LSV (16) 11
(1) Severe LSV þ IUGR (10) 8
(2) Severe LSV þ IUGR þ other brain anomalies(8) 7
(3) Severe LSV þ brain anomalies(11) 10
* Significance: p < 0.05.
CMV Z cytomegalovirus; IUGR Z intrauterine growth retardation; LSanalyzed using CMV urine PCR and only one was found to be
positive, which was significantly different from the new-
borns with LSV (p Z 0.003; OR Z 11.64; 95%
CI Z 0.81e166.53).
3.2. Developmental and neurodevelopmental
outcomes
Of the 20 newborns (10 males, 10 females) with CMV, 11
were term (gestational age 38 weeks) and nine were pre-
term. Seventeen infants had early developmental delays,
and 10 had a low body weight after follow-up (Table 3).
Three had hearing loss, including two with nonpickup
w95 dB, and one at 40 dB who improved to 30 dB after
ganciclovir treatment for 1 year.
Eighteen (90%) of the 20 newborns with a CMV-infection
had developmental delays, including nine with mild, four
with moderate, and five with severe delays. The outcomes
of the term and preterm infants were not significantly
different. The neurodevelopmental outcomes of those with
CMV infections in the two groups were not significantly
different, however the outcomes for 15 cases in whom CMV
infection was associated with other brain structural
anomalies found using MRI or computed tomography were
significantly worse than the outcomes in the cases associ-
ated with LSV only (p Z 0.029; Table 3).
4. Discussion
We found that the severity of LSV was strongly associated
with CMV infection. Even though many factors, including
exogenous and endogenous factors may result in LSV find-
ings, however their exact pathological mechanisms are
unclear. It is thought that prenatal, intrapartum, or post
natal brain insults from hypoxia, ischemia, or inflamma-
tion/calcification in these vessels leads to subtle vascular
changes, where the regions with relatively high blood flow
such as the basal ganglia and thalamus bear the
brunt.6,12,16,17 In addition, LSV was a more powerful pre-
dictor of CMV than IUGR, particularly when LSV was asso-
ciated with brain structural anomalies. By contrast, no
patients with IUGR had LSV, and only one had CMV. Isolated
IUGR without other anomalies therefore carried a lower risk
for CMV. This suggests that when brain ultrasonographyinfection (limited to specific signs).
þ CMV % Odds ratio p*
32 3 1.0
30 23 9.6 0.017
9 25 10.7 NS
3 67 64.0 0.000
1 75 96.0 0.002
5 69 70.4 0.000
2 80 128.0 0.000
1 88 224.0 0.000
1 91 320.0 0.000
V Z lenticulostriate vasculopathy; NS Z nonsignificant.
Table 3 Summary of magnetic resonance imaging and ultrasonography findings in newborns with congenital cytomegalovirus.
Case (#)z LSV
severity
Brain anomalies Neurodevelopment*
(Groups 1e4)
Hearing
threshold
(dB)y
Gender GA at
birth
(wk)
Time of
infection
(C/P)
Clinical
manifestations
Ganciclovir
treatment
DD IUGR
1 Marked Microcephaly, hypomyelination, malformations
of cortical development, white matter damage,
encephalomalacia, calcification
4 95, nonpickup F 39 C þ þ 2 wks (stopped
due to adverse
effects)
2 Marked Lissencephaly, pachygyria 4 30 M 37 C þ þ d
3 Marked White matter damage 4 N/A M 38 C þ þ d
4 Marked Multiple calcification, ventriculomegaly, porencephaly,
neuronal migration disorder, AgCC, cerebellar
hypoplasia
4 N/A M 39 P þ þ d
5 Marked Brain atrophy 3 30 M 26 P þ  6 wks
6 Marked Ventriculomegaly, bilateral occipital cysts 3 30 M 37 C þ þ d
7 Marked Temporal cyst, thin corpus callosum,
white matter damage
2 40 changed to
30 after
treatment
F 39 P þ  1 y
8 Marked Intracranial hemorrhage, calcification 2 30 M 40 P  þ d
9 Marked Subependymal cysts 2 30 F 36 C þ þ 6 wks
10 Marked d 2 30 F 28 P þ þ 6 wks
11 Marked Subdural effusion, mild brain atrophy 2 30 dB M 39 P  þ d
12 Marked Mild ventriculomegaly 2 30 dB F 40 P þ  d
13 Marked d 1 N/A F 39 P   d
14 Mild Subdural effusion and ventriculomegaly 4 30 dB M 40 P þ  d
15 Mild Mild ventriculomegaly, thin corpus callosum,
mega cisterna magna
3 95 dB,
nonpickup
M 35 C þ  d
16 Mild Subdural effusion, mild ventriculomegaly 3 30 dB F 34 P þ  d
17 Mild Thin corpus callosum 2 30 dB F 40 P þ þ d
18 Mild d 2 30 dB M 36 C  þ d
19 Mild d 2 30 dB F 31 P   d
20 Mild d 1 30 dB F 39 P þ  d
AgCC Z agenesis of the corpus callosum; C Z congenital; DD Z developmental delay; IUGR Z intrauterine growth retardation; N/A Z not available; P Z post infection.
* Neurodevelopment (Groups 1e4): Group 1, no neurological signs and no delay in developmental milestones; Group 2 (mild), mild
developmental delay; Group 3 (moderate), moderate developmental delay; and Group 4 (severe), severe developmental delay; time of
infection (C/P).
y Hearing deficiency was defined by the most quiet sounds their better ear could hear were above 30 dB.
z Cases 3, 8, 18, and 16 were LBW infants, and Cases 5 and 19 were VLBW infants.
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Cytomegalovirus Infection in Newborns 413shows LSV, a test for CMV should be performed, particularly
when the echogenicity of the LSV is marked and multi-
linear. The outcomes for cases in whom CMV infection was
associated with other brain structural anomalies were
significantly worse than the outcomes in cases associated
with LSV only.
Universal CMV screening tests using a dried blood sample
obtained shortly after birth are currently in use; however,
for regions without a policy of routine PCR screening for
CMV, brain ultrasonography can be used as an alternative
tool to detect CMV, particularly in asymptomatic newborns.
Universal screening of hearing in newborns is currently
performed in many countries. However, Fowler et al18 re-
ported that no CMV infections were identified during
hearing screening because the majority of CMV infections
involve a delayed onset of hearing loss which is asymp-
tomatic at birth. Neonatal screening of hearing alone is
therefore insufficient to detect all neonates with CMV
infection because most infants with congenital CMV have
normal hearing in the neonatal stage.19
Reports of imaging findings for CMV vary.19e21 One
study22 reported that ventricular dilatation was the most
common fetal ultrasonographic and MRI finding, followed
by periventricular calcification, microcephaly, and sub-
ependymal cyst. One case report21 reported that congenital
CMV was a cause of temporal cysts. However, in our case
series, we found that congenital cysts could occur in any
region, as in Patient 6, who had occipital porencephaly, and
Patient 7, who had a temporal cyst (Figure S1). Our findings
underscore the importance of brain ultrasonographic find-
ings of congenital and acquired CMV, including basal gan-
glion or thalamus hyperechogenicity, ventriculomegaly, and
destructive brain lesions (including brain cysts in any region
of the brain that should be highly suggestive of a CMV
infection). Our imaging findings showed that MRI increased
the positive predictive value but that ultrasonography and
MRI were not mutually exclusive, and brain ultrasonography
was more sensitive than MRI for detecting LSV. However,
standard brain ultrasonography has been reported to have
the best negative predictive value when done prenatally.21
Half of the children with symptomatic congenital CMV in-
fectionswill develop hearing loss5,9,18; however, themajority
will have a delayedonset or progressive hearing loss.18 In such
cases, anti-CMV medication can be used to prevent progres-
sive hearing impairment. In the present study, the hearing
level of one child given an antiviral drug for 1 year rose from
40 dB to 30 dB. Hearing impairment without an identified
cause is also suggestive of a CMV infection. Beginningmedical
treatment early depends on an early diagnosis. Congenital
CMV infections and connexin mutations are the two major
causes of deafness at birth.23 Our previous study analyzed
patients with nonsyndromic hearing loss in Taiwan, and indi-
cated that mutations of the CX gene family were responsible
forw24% of nonsyndromic hearing loss, with the cause of the
remaining 76% being unknown.24 In the current study, we
found that three of the 20 newborns with CMV infection had
hearing loss. Therefore, we suggest that further studies are
necessary to determine whether a CMV infection or other
genetic mutations are the major cause of hearing loss.
Ganciclovir therapy for newborns with congenital or
perinatal CMV disease, including symptomatic patients with
viral sepsis-like syndrome, pneumonitis or severethrombocytopenia, sight-threatening retinitis, combined
with primary immune disorders, and CMV infection has been
suggested,25 as it is believed that patients with symptoms
will have better outcomes than those without treatment.
However, the side effects of gancylocvir should be consid-
ered, which include lethal leucopenia. Newborns with CMV-
associated hearing impairment and central nervous system
involvement may benefit from long-term antiviral ther-
apy.25 Ganciclovir therapy of 6 mg/kg per dose adminis-
tered intravenously every 12 hours for 6 weeks beginning in
the neonatal period in symptomatic infants with CMV
infection involving the central nervous system has shown
apparent protection against hearing loss or progression of
the infection and improved head circumference growth and
neurodevelopmental milestones for the first 6e12 months
of life.26,27 Oral ganciclovir is an alternative choice with
lesser adverse effects than intravenous administration. For
patients without symptoms, no brain involvement or hear-
ing impairment, observation is suggested rather than
aggressive treatment which may contribute to unnecessary
adverse effects. We had one case with a temporal cyst, thin
corpus callosum, white matter change, and hearing
impairment who received intravenous and oral ganciclovir
treatment for 1 year, and the hearing outcome improved
from 40 dB to 30 dB with no obvious adverse effects except
for mild intelligence impairment at 4 years of age.
In this study, we found that severe LSV with marked
echogenic linear structures contributed to a more positive
result, which has not been reported previously. In a study
by Makhoul et al14 on 21 newborns with LSV, only one pa-
tient had a congenital CMV infection, which is inconsistent
with our study. This difference is probably because the
cases of LSV in their study were mild, leading to an
underestimated CMV infection rate. The ratio of bilateral
LSV in our study was 76%, which is similar to that in other
studies.14,17 An association of CMV and LSV (10e24% of 34
infants) was reported in study by Wang et al,17 which is
consistent with our study. However, more newborns had
severe LSV in our study than in their study. This highlights
that the degree of LSV in brain ultrasonography is an
important factor associated with CMV infection.
This study has a number of limitations. Firstly, a ma-
jority (80%) of the cases were selected from the NICU (level
III), and 13% were from the specialty care nursery (level II).
The large number of cases from the NICU may have resulted
in a larger proportion of cases with CMV infection in our
study sample. However, this highlights that newborns in the
NICU are at a high risk of CMV infection. In the IUGR group,
of the 72 patients without LSV, 33 had CMV detected in
urine PCR, possibly because of inconsistent policies of the
individual physicians. IUGR is not a specific symptom and
normal newborns would have been a better control group.
However, investigating normal newborns is difficult which is
why we chose those with symptoms of IUGR and without
LSV as the control group.5. Conclusion
The present study demonstrates that findings of LSV, and
particularly severe LSV, in neonatal ultrasonography were
correlated with CMV infection. When severe LSV is
414 S.-Y. Hong et alassociated with brain structural anomalies, a congenital
CMV infection should be considered. The outcomes of the
cases in which CMV infection was associated with other
brain structural anomalies were significantly worse than the
outcomes in the cases associated with LSV only.
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